JP2018511625A5 - - Google Patents

Download PDF

Info

Publication number
JP2018511625A5
JP2018511625A5 JP2017553410A JP2017553410A JP2018511625A5 JP 2018511625 A5 JP2018511625 A5 JP 2018511625A5 JP 2017553410 A JP2017553410 A JP 2017553410A JP 2017553410 A JP2017553410 A JP 2017553410A JP 2018511625 A5 JP2018511625 A5 JP 2018511625A5
Authority
JP
Japan
Prior art keywords
kit
hyperglycemia
chemotherapy
cancer
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017553410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018511625A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/028055 external-priority patent/WO2016168802A2/en
Publication of JP2018511625A publication Critical patent/JP2018511625A/ja
Publication of JP2018511625A5 publication Critical patent/JP2018511625A5/ja
Pending legal-status Critical Current

Links

JP2017553410A 2015-04-16 2016-04-18 正常細胞を保護し、かつラパマイシンおよびデキサメタゾンにより誘導される標準および高グルコース状態に反応して癌増感状態を生じさせる絶食模倣食(fmd)およびグルコース低下薬 Pending JP2018511625A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562148451P 2015-04-16 2015-04-16
US62/148,451 2015-04-16
PCT/US2016/028055 WO2016168802A2 (en) 2015-04-16 2016-04-18 Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020168000A Division JP2021008491A (ja) 2015-04-16 2020-10-02 正常細胞を保護し、かつラパマイシンおよびデキサメタゾンにより誘導される標準および高グルコース状態に反応して癌増感状態を生じさせる絶食模倣食(fmd)およびグルコース低下薬

Publications (2)

Publication Number Publication Date
JP2018511625A JP2018511625A (ja) 2018-04-26
JP2018511625A5 true JP2018511625A5 (enExample) 2019-01-10

Family

ID=57126369

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017553410A Pending JP2018511625A (ja) 2015-04-16 2016-04-18 正常細胞を保護し、かつラパマイシンおよびデキサメタゾンにより誘導される標準および高グルコース状態に反応して癌増感状態を生じさせる絶食模倣食(fmd)およびグルコース低下薬
JP2020168000A Pending JP2021008491A (ja) 2015-04-16 2020-10-02 正常細胞を保護し、かつラパマイシンおよびデキサメタゾンにより誘導される標準および高グルコース状態に反応して癌増感状態を生じさせる絶食模倣食(fmd)およびグルコース低下薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020168000A Pending JP2021008491A (ja) 2015-04-16 2020-10-02 正常細胞を保護し、かつラパマイシンおよびデキサメタゾンにより誘導される標準および高グルコース状態に反応して癌増感状態を生じさせる絶食模倣食(fmd)およびグルコース低下薬

Country Status (14)

Country Link
US (2) US20160303056A1 (enExample)
EP (2) EP3283073A4 (enExample)
JP (2) JP2018511625A (enExample)
KR (1) KR20180002677A (enExample)
CN (1) CN107613979A (enExample)
AU (1) AU2016248443B2 (enExample)
BR (1) BR112017022244A2 (enExample)
CA (2) CA2982875C (enExample)
HK (1) HK1249858A1 (enExample)
IL (1) IL255026A0 (enExample)
MX (1) MX2017013133A (enExample)
RU (1) RU2734774C2 (enExample)
WO (1) WO2016168802A2 (enExample)
ZA (1) ZA201707710B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2724525C2 (ru) * 2015-05-06 2020-06-23 Юниверсити Оф Саутерн Калифорния Способ лечения повышенных уровней инсулина или глюкозы с использованием гипокалорийного или бескалорийного рациона или рациона, имитирующего воздержание от пищи
MX2018009849A (es) 2016-02-15 2018-11-09 Univ Southern California Combinaciones de farmacos y metodos para estimular regeneracion de tipo embrionaria para tratar diabetes y otras enfermedades.
MX2018013727A (es) 2016-05-11 2019-08-29 Univ Southern California Dieta imitadora del ayuno (fmd) como un tratamiento inmunoregulador para enfermedades gastrointestinales autoinmunes/inflamatorias.
WO2018102393A1 (en) * 2016-11-30 2018-06-07 Cure Cancer Worldwide Llc System for chemotherapy delivery and method of the same
US11284640B2 (en) * 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
WO2019178486A1 (en) 2018-03-15 2019-09-19 University Of Southern California Fasting-mimicking diet (fmd) but not water-only fasting promotes reversal of inflammation and ibd pathology
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
US20220400732A1 (en) * 2019-03-21 2022-12-22 Cornell University Anti-fructose therapy for colorectal and small intestine cancers
CN114096164A (zh) 2019-04-30 2022-02-25 南加利福尼亚大学 作为阿尔茨海默病(ad)的干预措施的禁食模拟饮食(fmd)
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
WO2021257465A1 (en) * 2020-06-14 2021-12-23 L-Nutra, Inc. An intermittent fasting bar/drink that maintains and extends the fasting state
EP4180047A4 (de) * 2020-07-10 2024-03-13 Martynova, Elena Anatol'evna Verfahren zur durchführung eines fastenverlaufs für schwerkranke patienten

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050302A2 (en) * 2009-10-22 2011-04-28 University Of Southern California Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment
BR112013014076A2 (pt) * 2010-12-06 2016-11-22 Cure Cancer Worldwide Corp métodos de direcionamento metabólico de células de câncer usando quimio- e imunotherapia para tratamento de câncer
US9237761B2 (en) * 2013-02-12 2016-01-19 University Of Southern California Methods and diets for lowering glucose and/or IGF-1 levels
RU2672594C2 (ru) * 2013-07-01 2018-11-16 Юниверсити Оф Саутерн Калифорния Состояние воздержания от пищи в качестве диетического лечения диабета
EP3113776B1 (en) * 2014-03-06 2021-01-13 University of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues

Similar Documents

Publication Publication Date Title
JP2018511625A5 (enExample)
Ceresoli et al. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial
Fakih et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C
Chi et al. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer
Moorcraft et al. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience
RU2017136423A (ru) Рацион, имитирующий воздержание от пищи (fmd), и лекарственные средства, снижающие уровень глюкозы, защищают нормальные клетки и создают условия сенсибилизации при раке в ответ на стандартные условия и условия с высоким содержанием глюкозы, индуцированные рапамицином и дексаметазоном
Bischof et al. The potential of rapalogs to enhance resilience against SARS-CoV-2 infection and reduce the severity of COVID-19
Lewis et al. Feeding tube use in patients with head and neck cancer
KR102154458B1 (ko) 공복 조건들 하에서의 타시멜테온의 투여
JP2013508411A5 (enExample)
Iñiguez-Ariza et al. Salvage lenvatinib therapy in metastatic anaplastic thyroid cancer
JP2016528162A5 (enExample)
Sharma et al. Molecular aspects and therapeutic implications of herbal compounds targeting different types of cancer
Roy et al. Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study
JP2017503846A5 (enExample)
JP2020523375A5 (enExample)
Prasanna et al. Efficacy and safety of DoceAqualip in a patient with locally advanced cervical cancer: a case report
Mokrim et al. Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature
Lee et al. Severe ileitis associated with capecitabine: two case reports and review of the literature
Sugimoto et al. Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402)
Hoang et al. Palliative treatment for advanced biliary adenocarcinomas with combination dimethyl sulfoxide–sodium bicarbonate infusion and S-adenosyl-l-methionine
Chalasani Optimizing quality of life in patients with hormone receptor-positive metastatic breast cancer: treatment options and considerations
Chaudhary et al. A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer
Crumbaker et al. Dose considerations for anti‐cancer drugs in metastatic prostate cancer
Melichar et al. Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial